keyword
MENU ▼
Read by QxMD icon Read
search

lung adenocarcinoma brain metastases egfr

keyword
https://www.readbyqxmd.com/read/27892978/estimating-survival-in-patients-with-lung-cancer-and-brain-metastases-an-update-of-the-graded-prognostic-assessment-for-lung-cancer-using-molecular-markers-lung-molgpa
#1
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
Importance: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Objective: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27888377/correlation-between-status-of-epidermal-growth-factor-receptor-mutation-and-distant-metastases-of-lung-adenocarcinoma-upon-initial-diagnosis-based-on-1063-patients-in-china
#2
Hongwei Li, Jianzhong Cao, Xiaqin Zhang, Xing Song, Weili Wang, Sufang Jia, Zhengran Li, Haixia Jia, Xing Cao, Wei Zhou, Jianhong Lian, Songye Han, Weihua Yang, Yanfen Xi, Shenming Lian, Haoxing Jing
The study aimed to explore the correlations between status of epidermal growth factor receptor (EGFR) mutations and distant metastases. A total of 1063 patients with lung adenocarcinoma indentified with status of EGFR mutations from August 2010 to May 2015 at Shanxi Cancer Hospital were enrolled. 456 patients were confirmed with EGFR mutations. The associations among EGFR mutations, clinical factors, and distant metastases at initial diagnosis were evaluated. Patients harboring EGFR mutation were more likely to be female (P < 0...
November 25, 2016: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/27675604/comparing-the-clinical-efficacy-of-tki-alone-with-tki-plus-concomitant-wbrt-for-egfr-mutation-positive-lung-adenocarcinoma-patients-with-brain-metastases-a-retrospective-study
#3
H Ge, Q Zhu, Y Sun
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27627582/first-line-egfr-tki-alone-or-with-whole-brain-radiotherapy-for-brain-metastases-in-egfr-mutated-lung-adenocarcinoma-patients
#4
Yongshun Chen, Jing Yang, Xue Li, Daxuan Hao, Xiaoyuan Wu, Yuanyuan Yang, Chunyu He, Wen Wang, Jianhua Wang
We proposed to compare the outcome of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone with EGFR-TKI plus whole-brain radiotherapy (WBRT) in treatment of brain metastases (BM) from EGFR-mutated lung adenocarcinoma patients. 1665 patients were screened from 2008 to 2014, and 132 were enrolled in our study. Among the 132 patients, 72 (54.5%) harbored a deletion in exon 19, 97 (73.5%) showed multiple intracranial lesions, and 67 (50.8%) had asymptomatic BM. 79 patients (59...
September 14, 2016: Cancer Science
https://www.readbyqxmd.com/read/27598807/the-effect-of-gene-alterations-and-tyrosine-kinase-inhibition-on-survival-and-cause-of-death-in-patients-with-adenocarcinoma-of-the-lung-and-brain-metastases
#5
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
PURPOSE: Lung cancer remains the most common cause of both cancer mortality and brain metastases (BM). The purpose of this study was to assess the effect of gene alterations and tyrosine kinase inhibition (TKI) on median survival (MS) and cause of death (CoD) in patients with BM from lung adenocarcinoma (L-adeno). METHODS: A multi-institutional retrospective database of patients with L-adeno and newly diagnosed BM between 2006 and 2014 was created. Demographics, gene alterations, treatment, MS, and CoD were analyzed...
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27561804/-analysis-of-clinicopathological-feature-and-prognosis-for-%C3%A2-leptomeningeal-metastasis-in-non-small-cell-lung-cancer
#6
Min Zhu, Yanhong Ren, Yan Liu, Chengjun Ban, Hua Gu, Zheng Wang, Yuhui Zhang
BACKGROUND: Leptomeningeal metastases (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) due to the lower quality of life and poor prognosis. The aim of this study is to analyze the clinicopathological features and prognosis of patients with LM from NSCLC (NSCLC-LM). METHODS: Clinical data of 3 patients with NSCLC-LM collected from January 2015 to June 2016 were analyzed with a brief review. RESULTS: All 3 patients had adenocarcinoma histology harboring epidermal growth factor receptor (EGFR) exon 21 point mutations (m)...
August 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27486770/a-retrospective-analysis-in-patients-with-egfr-mutant-lung-adenocarcinoma-is-egfr-mutation-associated-with-a-higher-incidence-of-brain-metastasis
#7
Guang Han, Jianping Bi, Wenyong Tan, Xueyan Wei, Xiaohong Wang, Xiaofang Ying, Xiaofang Guo, Xiaoyi Zhou, Desheng Hu, Weining Zhen
Lung adenocarcinomas are more commonly associated with brain metastases (BM). Epidermal growth factor receptor (EGFR) mutations have been demonstrated to be both predictive and prognostic for patients with lung adenocarcinoma. We aimed to explore the potential association between EGFR mutation and the risk of BM in pulmonary adenocarcinoma patients. Data of 234 patients from 2007 to 2014 were retrospectively reviewed. A total of 108 patients had EGFR mutations in the entire cohort. Among them, 76 patients developed BM during their disease course...
July 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27446584/quick-regression-of-brain-metastases-from-lung-adenocarcinoma-with-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-treatment-a-case-report-and-literature-review
#8
Huaqiong Huang, Shuangli Zhu, Shaobin Wang, Wen Li
Brain metastasis (BM) commonly occurs in patients with advanced lung cancer, and is associated with poor prognosis and limited treatment options, particularly for end-stage patients who are in poor physical and mental state. We herein present a case of lung adenocarcinoma with BM, as revealed by tumor marker and imaging studies. The patient was a 74-year-old woman who was diagnosed with lung adenocarcinoma with several metastatic lesions in the mediastinal lymph nodes, bone and brain. The patient underwent two cycles of chemotherapy, but the cancer recurred with enlarged BM, resulting in confusion and body dysfunction...
August 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27347151/bevacizumab-to-combat-egfr-tki-resistance-in-a-patient-with-advanced-non-small-cell-lung-cancer-harboring-an-egfr-mutation-a-case-report
#9
Zhiyi Wang, P U Zhou, Guanghui Li
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the first-line strategy for patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations. Acquired resistance to EGFR-TKIs is inevitable in patients receiving EGFR-TKI therapy. Treatment with bevacizumab can induce a marked improvement in the overall and progression-free survival of patients with NSCLC; however, the effect of bevacizumab on TKI resistance in patients with NSCLC with an activating EGFR mutation is largely unknown...
July 2016: Oncology Letters
https://www.readbyqxmd.com/read/27298405/management-of-brain-metastases-in-alk-positive-non-small-cell-lung-cancer
#10
Chad G Rusthoven, Robert C Doebele
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
August 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27186518/erlotinib-plus-concurrent-whole-brain-radiation-therapy-for-non-small-cell-lung-cancers-patients-with-multiple-brain-metastases
#11
Danny Ulahannan, Siow-Ming Lee
Sequencing of the epidermal growth factor receptor (EGFR) gene to identify mutations in lung adenocarcinomas is routine in clinical practice. The use of tyrosine kinase inhibitors (TKIs) has transformed the management of patients with brain metastases harboring EGFR mutations, with improved response rates (RR) and survival. We evaluate the role of concurrent TKI therapy and radiotherapy in this group of patients, considering this data in the context of emerging concepts in this advancing field.
April 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27143936/comparison-of-erlotinib-and-pemetrexed-as-second-third-line-treatment-for-lung-adenocarcinoma-patients-with-asymptomatic-brain-metastases
#12
Yayi He, Wenwen Sun, Yan Wang, Shengxiang Ren, Xuefei Li, Jiayu Li, Christopher J Rivard, Caicun Zhou, Fred R Hirsch
OBJECTIVE: Brain metastases occur in one-third of all non-small-cell lung cancer patients. Due to restrictive transport at the blood-brain barrier, many drugs provide poor control of metastases in the brain. The aim of this study was to compare erlotinib with pemetrexed as second-/third-line treatment in patients with lung adenocarcinoma with asymptomatic brain metastases. METHODS: From January 2012 to June 2014, all lung adenocarcinoma patients with asymptomatic brain metastases who received treatment with erlotinib or pemetrexed as second-/third-line treatment were retrospectively reviewed...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27070580/discordance-of-mutation-statuses-of-epidermal-growth-factor-receptor-and-k-ras-between-primary-adenocarcinoma-of-lung-and-brain-metastasis
#13
Kun-Ming Rau, Han-Ku Chen, Li-Yen Shiu, Tsai-Ling Chao, Yi-Ping Lo, Chin-Chou Wang, Meng-Chih Lin, Chao-Cheng Huang
Mutations on epidermal growth factor receptor (EGFR) of adenocarcinomas of lung have been found to be associated with increased sensitivity to EGFR tyrosine kinase inhibitors and K-ras mutations may correlate with primary resistance. We aimed to explore the discordant mutation statuses of EGFR and K-ras between primary tumors and matched brain metastases in adenocarcinomas of lung. We used a sensitive Scorpion ARMS method to analyze EGFR mutation, and Sanger sequencing followed by allele-specific real-time polymerase chain reaction to analyze K-ras mutation...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27034176/impact-of-deferring-radiation-therapy-in-patients-with-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-who-develop-brain-metastases
#14
William J Magnuson, Jacky T Yeung, Paul D Guillod, Scott N Gettinger, James B Yu, Veronica L Chiang
PURPOSE: To perform a retrospective analysis of patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma who developed brain metastases (BM) to evaluate our hypothesis that the use of upfront EGFR-tyrosine kinase inhibitors (TKIs), and deferral of radiation therapy (RT), would result in inferior intracranial progression-free survival but similar overall survival (OS). METHODS AND MATERIALS: Of 202 patients diagnosed with EGFR-mutant NSCLC between July 1, 2008, and December 31, 2014, 71 developed BM...
June 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26823294/first-line-afatinib-versus-chemotherapy-in-patients-with-non-small-cell-lung-cancer-and-common-epidermal-growth-factor-receptor-gene-mutations-and-brain-metastases
#15
Martin Schuler, Yi-Long Wu, Vera Hirsh, Kenneth O'Byrne, Nobuyuki Yamamoto, Tony Mok, Sanjay Popat, Lecia V Sequist, Dan Massey, Victoria Zazulina, James C-H Yang
INTRODUCTION: Metastatic spread to the brain is common in patients with non-small cell lung cancer (NSCLC), but these patients are generally excluded from prospective clinical trials. The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article...
March 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/26743855/egfr-mutation-impact-on-definitive-concurrent-chemoradiation-therapy-for-inoperable-stage-iii-adenocarcinoma
#16
Kosuke Tanaka, Toyoaki Hida, Yuko Oya, Tomoyo Oguri, Tatsuya Yoshida, Junichi Shimizu, Yoshitsugu Horio, Akito Hata, Reiko Kaji, Shiro Fujita, Yoshitaka Sekido, Takeshi Kodaira, Masaki Kokubo, Nobuyuki Katakami, Yasushi Yatabe
BACKGROUND: Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung adenocarcinoma; however, little has been reported about the impact of epidermal growth factor receptor (EGFR) mutation on CRT efficacy. METHODS: From 2006 to 2013, we retrospectively screened 104 unresectable stage III adenocarcinoma patients who were examined for EGFR mutation status and received definitive concurrent CRT consisting of platinum doublet chemotherapy in first-line setting and compared the clinical outcomes and recurrence patterns according to mutation status...
December 2015: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/26700783/-a-case-of-cardiac-tamponade-due-to-malignant-pericarditis-with-lung-adenocarcinoma-effectively-treated-with-pericardial-drainage-and-pemetrexed-plus-cisplatin-chemotherapy
#17
Kazufumi Yoshida, Shinji Teramoto
A 68-year-old man was diagnosed with non small cell lung cancer in May 2013. Although the patient was negative for EGFR mutation, he wished to undergo treatment with gefitinib and erlotinib as first-line therapy. However, one year later, he was admitted to our hospital because of cardiac tamponade due to malignant pericarditis. He received pericardial drainage, after which his condition was stabilized. He was diagnosed with lung adenocarcinoma by cytology of pericardial effusion and treated with pemetrexed plus cisplatin as second-line therapy...
2015: Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
https://www.readbyqxmd.com/read/26639246/radiotherapy-effects-on-brain-bone-metastatic-adenocarcinoma-lung-cancer-and-the-importance-of-egfr-mutation-test
#18
B L Qu, B N Cai, W Yu, F Liu, Y R Huang, Z J Ju, X S Wang, G M Ou, L C Feng
This study proposed to retrospectively analyze the efficacy of radiotherapy on brain/bone metastases in patients with stage IV lung adenocarcinoma and to evaluate the correlation between overall survival after radiotherapy and other factors including metastatic sites and EGFR mutation status. 115 patients with Stage IV lung adenocarcinoma admitted to our center from March, 2011 to December, 2013 were enrolled. They presented with metastases to no other solid organs except the bone or brain and had received no prior treatment...
2016: Neoplasma
https://www.readbyqxmd.com/read/26519739/different-spatial-distributions-of-brain-metastases-from-lung-cancer-by-histological-subtype-and-mutation-status-of-epidermal-growth-factor-receptor
#19
Koji Takano, Manabu Kinoshita, Masatoshi Takagaki, Mio Sakai, Souichirou Tateishi, Takamune Achiha, Ryuichi Hirayama, Kazumi Nishino, Junji Uchida, Toru Kumagai, Jiro Okami, Atsushi Kawaguchi, Naoya Hashimoto, Katsuyuki Nakanishi, Fumio Imamura, Masahiko Higashiyama, Toshiki Yoshimine
BACKGROUND: The purpose of this study was to test the hypothesis that the genetic backgrounds of lung cancers could affect the spatial distribution of brain metastases. METHODS: CT or MR images of 200 patients with a total of 1033 treatment-naive brain metastases from lung cancer were retrospectively reviewed (23 by CT and 177 by MRI). All images were standardized to the human brain MRI atlas provided by the Montreal Neurological Institute 152 database. Locations, depths from the brain surface, and sizes of the lesions after image standardization were analyzed...
May 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26469914/afatinib-in-treatment-naive-patients-with-egfr-mutated-lung-adenocarcinoma-with-brain-metastasis-a-case-series
#20
Shih-Hong Li, Meng-Heng Hsieh, Yueh-Fu Fang
Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) were previously the standard first-line treatments for lung cancers with activating EGFR mutations. The first-generation reversible EGFR TKIs, gefitinib and erlotinib, demonstrated substantial efficacy in the treatment of brain metastases from EGFR-mutated lung adenocarcinoma. However, the efficacy of afatinib, the second-generation irreversible EGFR TKI, as the first-line treatment in lung adenocarcinoma patients with brain metastasis has yet to be evaluated...
October 2015: Medicine (Baltimore)
keyword
keyword
98956
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"